Graft-versus-host Disease
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-12-14FDA Approved: CYCLOSPORINE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approves Teva Pharmaceuticals' generic cyclosporine under an original application (ANDA 203880), expanding access to this immunosuppress…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) [Phase 2]
Phase 2 study evaluating high-dose post-transplant cyclophosphamide plus bortezomib (CyBor) for preventing graft-versus-host disease after a…
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: Treatment of Oral Chronic Graft-versus-host Disease With Human Umbilical Cord Mesenchymal Stem Cell Dressing [Phase 4]
Phase 4 trial update investigating human umbilical cord mesenchymal stem cell dressing for oral chronic graft-versus-host disease.
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: First Line Therapy for High Risk Acute GVHD [Phase 2]
Phase 2 trial update on first-line therapy for high-risk acute graft-versus-host disease (aGVHD) in stem cell transplant patients. Completed…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT [Phase 1, Phase 2]
Clinical trial of ibritinib plus rituximab for chronic graft-versus-host disease after allogeneic stem cell transplant was terminated; resul…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation [Phase 2]
Phase 2 trial update evaluating Anti T-lymphocyte Immunoglobulin with post-transplant cyclophosphamide to prevent GVHD after allogeneic tran…
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease [Phase 1, Phase 2]
A Phase 1/2 trial evaluating safety and efficacy of Efavaleukin Alfa in steroid-refractory chronic graft-versus-host disease (cGVHD) has bee…
-
CLINICAL_TRIALS trial_result · 2023-11-15Clinical Trial Update: Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD [Phase 2]
Phase 2 trial update comparing steroids versus extracorporeal photopheresis (ECP) and steroids as first-line treatment for Grade II acute gr…
-
FDA approval · 2023-11-09FDA Approved: REZUROCK — Supplemental Application (Kadmon Pharmaceuticals, LLC)
FDA approved a supplemental application for REZUROCK (belumosudil) from Kadmon Pharmaceuticals, LLC.
-
CLINICAL_TRIALS trial_result · 2023-11-08Clinical Trial Update: Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention [Phase 1, Phase 2]
This clinical trial update reports results from Phase 1/2 trials evaluating a three-drug regimen of cyclophosphamide, abatacept, and tacroli…
-
CLINICAL_TRIALS trial_result · 2023-11-01Clinical Trial Update: Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD) [Phase 2]
Phase 2 trial update assessing efficacy and safety of BN101 in subjects with chronic graft-versus-host disease (cGVHD).
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]
Phase 1/2 clinical trial investigated the JAK1/2 inhibitor baricitinib for chronic graft-versus-host disease following allogeneic hematopoie…
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression [Phase 1, Phase 2]
Phase I/II trial evaluating pacritinib in combination with sirolimus-based immunosuppression for the prevention of graft-versus-host disease…
-
CLINICAL_TRIALS trial_result · 2023-10-11Clinical Trial Update: Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases [Phase 2]
Phase 2 clinical trial evaluating donor stem cell transplantation followed by cyclophosphamide for hematological diseases; status completed …
-
CLINICAL_TRIALS trial_result · 2023-10-04Clinical Trial Update: Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement [Phase 4]
Phase 4 trial evaluating vedolizumab and an anti-CD25 antibody for rapid reduction of glucocorticoids in steroid-refractory acute graft-vers…
-
CLINICAL_TRIALS trial_result · 2023-10-03Clinical Trial Update: A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4) [Phase 2]
Phase 2 safety study of liposomal cyclosporine A for bronchiolitis after hematopoietic cell transplantation was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Gut Decontamination In Pediatric Allogeneic Hematopoietic [Phase 2]
Phase 2 trial update on gut decontamination in pediatric allogeneic hematopoietic stem cell transplantation with data posted after completio…
-
CLINICAL_TRIALS trial_result · 2023-08-21Clinical Trial Update: Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis [Phase 3]
Phase 3 clinical trial evaluating different doses of post-transplant cyclophosphamide for graft-versus-host disease prophylaxis after transp…
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids [Phase 2]
Phase 2 study evaluating ruxolitinib for sclerotic chronic graft-versus-host disease after failure of systemic glucocorticoids has completed…
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease [Phase 2]
Phase 2 trial update investigating letermovir prophylaxis for CMV in patients with graft-versus-host disease.
-
CLINICAL_TRIALS trial_result · 2023-07-17Clinical Trial Update: Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant [Phase 3]
Phase 3 trial evaluating whether Lactobacillus plantarum can prevent acute graft-versus-host disease in children undergoing donor stem cell …
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease [Phase 2]
Phase 2 trial evaluating KD025 for safety, tolerability, and activity in chronic graft-versus-host disease has completed with posted results…
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT [Phase 2]
Phase 2 clinical trial update evaluating a humanized anti-CD25 antibody for prophylaxis of acute graft-versus-host disease in elderly patien…
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Ruxolitinib as GVHD Prophylaxis in AA Patients [Phase 2]
Phase 2 trial evaluating ruxolitinib as prophylaxis for acute GVHD in patients undergoing HSCT for acquired aplastic anemia (AA).
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …